# Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies

> **NCT02387164** · PHASE2 · TERMINATED · sponsor: **Lund University** · enrollment: 26 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1
- Prediabetic State

## Interventions

- **DRUG:** Alum-GAD
- **DRUG:** Vitamin D3

## Key facts

- **NCT ID:** NCT02387164
- **Lead sponsor:** Lund University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-09
- **Primary completion:** 2019-10-07
- **Final completion:** 2019-10-07
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** The study was interrupted early and terminated when only 26 out of 80 patients were enrolled due to new clinical study results indicating that the current study would not be informative.
- **Last updated:** 2020-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387164, "Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02387164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*